Overall, GCN5 HAT inhibition disrupts BCR signaling and reduces phosphorylation of key effectors, thereby reducing viability and inducing apoptosis in Burkitt lymphoma cells. The gene discussed is KAT2B; the disease is Burkitt lymphoma.